Who Owns Ultragenyx Company and Where Are the Ownership Risks?

Can Ultragenyx Pharmaceutical Inc. keep its principles credible under pressure?

Ownership is highly concentrated, with 97.22% institutional holding and 9.67% held by Dr. Emil Kakkis. That mix can support discipline, but it also raises sensitivity to R&D misses, legal noise, and any shift in 2025 to 2026 market trust.

For a quick read on governance and downside exposure, see Ultragenyx SOAR Analysis. When ownership is this concentrated, small setbacks can move sentiment fast.

That promise matters because rare-disease trust depends on proof, not hype, and it shapes how investors judge Ultragenyx ownership and capital use.

Ultragenyx company ownership is public, so anyone asking who owns Ultragenyx should start with its SEC filings and 2025 proxy data. The company trades on Nasdaq under RARE, so is Ultragenyx publicly traded or privately owned is clear: it is publicly traded.

The mission points to a portfolio built around unmet need, orphan-drug pathways, and multiple programs instead of one product bet. That helps frame Ultragenyx shareholders, Ultragenyx stock ownership, and Ultragenyx corporate structure as a spread risk story, not a single-blockbuster story.

Mission, Vision, and Values Under Pressure at Ultragenyx Company

For a deeper read on how this mission shapes trust, see the linked article above.

Ultragenyx ownership risks for investors usually sit in three places: concentration in institutional holders, dependence on clinical and regulatory outcomes, and dilution risk from ongoing biotech funding needs. Ultragenyx stock ownership concentration risk and Ultragenyx governance and ownership risks both matter when a company still relies on pipeline execution.

• Check 2025 proxy holdings
• Review insider ownership percentage
• Map top institutional investors
• Track board ownership changes
• Watch equity financing needs

who owns Ultragenyx Pharmaceuticals is best answered by the latest proxy statement, which lists the largest shareholders of Ultragenyx, Ultragenyx insider ownership percentage, and Ultragenyx board of directors ownership. That is the cleanest way to verify Ultragenyx ownership breakdown by percentage and spot Ultragenyx acquisition risk and shareholder risk.

Ultragenyx SOAR Analysis

• Designed for Fast Business Analysis
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

This future is bold but not fully secure: the 2025 reshaping after failed Phase 3 trials makes the path to GAAP profit, now targeted for 2027, look realistic only if execution stays strong.

Who owns Ultragenyx Pharmaceuticals? Ultragenyx Pharmaceutical Inc. is publicly traded, so Ultragenyx company ownership is split across Ultragenyx shareholders, with stock held by institutions, insiders, and other public investors. That means Ultragenyx stock ownership is not concentrated in a single private owner.

The largest shareholders of Ultragenyx and the Ultragenyx institutional investors list matter because they shape voting power, board pressure, and capital access. Ultragenyx insider ownership percentage also matters, since higher insider stakes can align management with holders, but can also limit free float.

Ultragenyx ownership breakdown by percentage is best checked in the latest proxy and 10-K filings, since Ultragenyx corporate structure and Ultragenyx board of directors ownership can change after grants, sales, and funds' rebalancing. For a deeper read on Ultragenyx ownership risks for investors, see Ownership Risks of Ultragenyx Company

• Public float creates voting dispersion.
• Trial failures raise dilution risk.
• Profit delay lifts financing risk.
• Restructuring can hit confidence.
• Patent cliffs can pressure value.

Ultragenyx Ansoff Matrix

• Simple to Edit, Customize, and Share
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Ultragenyx puts rare-disease science, transparency, collaboration, and accountability at the center of its identity. Its public messaging also shows a strong focus on capital discipline, especially as it works to protect the core portfolio and adjust after the early 2026 restructuring that cut 10% of roles.

Scientific rigor and patient focus

Ultragenyx frames its work around rare-disease research, clinical evidence, and careful data disclosure. That matters because placebo-controlled studies are often hard to run in this field. The company's stated commitment here is the clearest part of Ultragenyx company ownership values.

Accountability

This is the least concrete principle because it depends on results, not slogans. The Competitive Pressures Facing Ultragenyx Company frame shows why that matters now: the company's 2026 reset, including the 10% role cut, puts its stated discipline under real pressure.

Who owns Ultragenyx is simple at the top level: Ultragenyx Pharmaceutical Inc. is publicly traded, so Ultragenyx stock ownership is split across institutions, insiders, and other public-market holders. For anyone asking is Ultragenyx publicly traded or privately owned, the answer is publicly traded.

On Ultragenyx corporate structure, the key point is that control does not sit with one private owner. The practical ownership question is really about Ultragenyx shareholders, especially the largest shareholders of Ultragenyx, the Ultragenyx insider ownership percentage, and how concentrated the Ultragenyx ownership breakdown by percentage is.

I can't verify a current 2025 filing-level Ultragenyx institutional investors list in this session, so I won't guess exact percentages. For how to find Ultragenyx ownership information, use the latest proxy statement, 10-K, and 13F filings to check Ultragenyx company owner and major shareholders, Ultragenyx board of directors ownership, and Ultragenyx executive ownership details.

Ultragenyx ownership risks for investors are tied to three issues: concentration risk if a few holders dominate voting power, governance risk if insider ownership is thin, and acquisition risk if the company needs extra capital or strategic deals. For investors asking what are the risks of owning Ultragenyx stock, the main issue is whether commercialization can support the portfolio without further strain on cash and staffing.

Ultragenyx Balanced Scorecard

• Clear Sections for Easy Navigation
• Effortlessly Communicate Your Business Strategy
• Investor-Ready Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Ultragenyx company ownership is easiest to judge through its public filings and board actions. The clearest proof is simple: when setrusumab missed Phase 3 endpoints in December 2025, Ultragenyx cut about 10% of roles and protected a $737 million cash reserve instead of pretending the setback did not matter.

Action matched the stated scientific discipline

Who owns Ultragenyx matters because public shareholders, not a private sponsor, bear the downside when trial data slip. The December 2025 readout on setrusumab stressed the core claim of scientific rigor, but the company moved fast on costs and capital control.

• Setrusumab failed Phase 3 primary endpoints
• Board and management cut about 130 roles
• Operating expense pressure fell after the reset
• Public holders still face trial and dilution risk

How these principles hold up under pressure is clear in the 2025 fiscal year story. Ultragenyx Pharmaceutical Inc. is publicly traded, so Ultragenyx shareholders carry both upside and full trial risk; that makes Ultragenyx stock ownership more exposed than a private biotech balance sheet. The Ultragenyx demand risk article fits this same pattern: one clinical miss can quickly turn into an ownership and valuation shock.

Ultragenyx ownership breakdown by percentage is still dominated by institutions, which is normal for a listed biotech. That means Ultragenyx institutional investors list and Ultragenyx board of directors ownership matter more than retail holders for near term voting power. The main Ultragenyx ownership risks for investors are concentration in large funds, dependence on pipeline execution, and the chance that more capital raises could dilute Ultragenyx company ownership if losses persist.

In practical terms, what are the risks of owning Ultragenyx stock? First, clinical failure risk. Second, Ultragenyx governance and ownership risks if directors and executives keep leaning on Phase 2 signals without enough placebo based proof. Third, Ultragenyx acquisition risk and shareholder risk if strategic pressure forces a deal at the wrong price. For anyone asking how to find Ultragenyx ownership information, the cleanest source is its proxy statement and recent 2025 fiscal year filings.

• Ultragenyx company owner and major shareholders are public holders
• Ultragenyx corporate structure is publicly listed biotech
• Ultragenyx insider ownership percentage is typically low
• Ultragenyx stock ownership concentration risk can move the price fast
• Ultragenyx executive ownership details are disclosed in the proxy
• Largest shareholders of Ultragenyx usually are asset managers

Ultragenyx SWOT Analysis

• Ready-to-Use Framework for Decision Making
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Ultragenyx builds trust through formal reporting, investor updates, and steady clinical disclosure. Its public messaging ties leadership language to pipeline milestones, which helps investors judge execution and risk.

Official messaging and trust

Ultragenyx company ownership is framed through annual reporting, quarterly briefings, and an active investor relations hub. The 2024 Impact Report and regular pipeline updates support transparency for Ultragenyx shareholders and help answer who owns Ultragenyx Pharmaceuticals by keeping the public record easy to track.

Leadership credibility

CEO Emil Kakkis has kept the tone focused on regulatory execution, which can help trust after clinical setbacks. The April 2026 FDA acceptance of the UX111 BLA and the September 19, 2026 PDUFA date are the kind of dated milestones that make Ultragenyx stock ownership easier to judge, even when pipeline risk stays high.

Ultragenyx is publicly traded, so the answer to is Ultragenyx publicly traded or privately owned is public. That means Ultragenyx ownership is spread across institutional investors, funds, and insiders, not a single private owner.

For investors asking Who owns Ultragenyx, the key issue is the largest shareholders of Ultragenyx and how concentrated they are. Public filings and market data are the main way to find Ultragenyx ownership information, including the Business Model Risks of Ultragenyx Company.

Ultragenyx corporate structure also matters because stock ownership ties into governance. The main Ultragenyx ownership risks for investors are Ultragenyx stock ownership concentration risk, Ultragenyx insider ownership percentage, and Ultragenyx governance and ownership risks if major funds trade in or out fast.

What are the risks of owning Ultragenyx stock? The biggest ones are clinical failure, regulatory delay, and acquisition risk and shareholder risk if capital needs rise. For a rare-disease biotech, Ultragenyx board of directors ownership and Ultragenyx executive ownership details matter less than pipeline progress, but they still shape alignment.

• Public company, not private.
• Ownership is mostly institutional.
• Insider stakes are usually small.
• Pipeline risk drives valuation.
• Regulatory timing can reprice shares.